Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea
Contrary to the United States Food and Drug Administration's safety warning, our findings suggest that dapagliflozin may have a protective effect against AKI in patients with T2DM. This is consistent with recent findings from European post-marketing safety studies and may serve as supportive evidence.
Authors
- Haerin Cho (ORCID: https://orcid.org/0009-0001-7221-4265)
- Na‐Young Jeong (ORCID: https://orcid.org/0000-0003-2130-1286)
- Ye‐Jee Kim (ORCID: https://orcid.org/0000-0002-3307-2970)
- Suvin Park (ORCID: https://orcid.org/0000-0003-4292-049X)
- HoJin Shin (ORCID: https://orcid.org/0000-0002-2032-6134)
- Nam‐Kyong Choi
- Heehyun Won (ORCID: https://orcid.org/0000-0001-9601-3786)
- Jeong Ah Kim (ORCID: https://orcid.org/0000-0001-5429-759X)
- Hee‐Jin Kim (ORCID: https://orcid.org/0000-0003-0424-8874)
- Hui‐Eon Lee (ORCID: https://orcid.org/0000-0002-6351-2674)
Institutions
- Ulsan College (KR)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Ewha Womans University (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1002/phar.70015
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Ministry of Food and Drug Safety